Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Export

@article{citeulike:2087276, abstract = {Tuberculosis is re-emerging in patients with altered immune status, such as those with chronic renal failure. Clinicians should thus be aware of the pharmacokinetics and dosage adjustment of antitubercular drugs in patients with renal insufficiency. Among patients with renal insufficiency, those who are dialysed should be treated with special care. Indeed, dosage should always be closely adjusted in these patients and potential removal by dialysis must be taken into account. However reliable the dosage adjustment recommendations are for these drugs in patients with renal failure, further pharmacokinetic investigations need to be performed, especially in dialysis patients in whom the influence of haemodialysis and continuous ambulatory peritoneal dialysis on drug pharmacokinetics needs to be detailed. In the meantime, it could be generally advised to administer all antitubercular drugs after the haemodialysis session, even though some drugs are known to be non-dialysable.}, address = {Department of Nephrology, Pitie-Salpetriere Hospital, Paris, France. vincent.launay-vacher@psl.ap-hop-paris.fr}, author = {Launay-Vacher, V. and Izzedine, H. and Deray, G.}, citeulike-article-id = {2087276}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/15762766}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=15762766}, issn = {0312-5963}, journal = {Clin Pharmacokinet}, keywords = {ckd, ethambutol, insufficiency, launay-vacher, moxifloxacin, pyrazinamide, renal, rifampicin, rifampin, tuberculosis}, number = {3}, pages = {221--235}, posted-at = {2007-12-11 00:20:05}, priority = {0}, title = {Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/15762766}, volume = {44}, year = {2005} }

TY - JOUR ID - citeulike:2087276 L3 - citeulike-article-id:2087276 N2 - Tuberculosis is re-emerging in patients with altered immune status, such as those with chronic renal failure. Clinicians should thus be aware of the pharmacokinetics and dosage adjustment of antitubercular drugs in patients with renal insufficiency. Among patients with renal insufficiency, those who are dialysed should be treated with special care. Indeed, dosage should always be closely adjusted in these patients and potential removal by dialysis must be taken into account. However reliable the dosage adjustment recommendations are for these drugs in patients with renal failure, further pharmacokinetic investigations need to be performed, especially in dialysis patients in whom the influence of haemodialysis and continuous ambulatory peritoneal dialysis on drug pharmacokinetics needs to be detailed. In the meantime, it could be generally advised to administer all antitubercular drugs after the haemodialysis session, even though some drugs are known to be non-dialysable. IS - 3 JF - Clin Pharmacokinet SN - 0312-5963 AD - Department of Nephrology, Pitie-Salpetriere Hospital, Paris, France. vincent.launay-vacher@psl.ap-hop-paris.fr EP - 235 TI - Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. VL - 44 SP - 221 KW - ckd KW - ethambutol KW - insufficiency KW - launay-vacher KW - moxifloxacin KW - pyrazinamide KW - renal KW - rifampicin KW - rifampin KW - tuberculosis AU - Launay-Vacher, V AU - Izzedine, H AU - Deray, G PY - 2005/// UR - http://view.ncbi.nlm.nih.gov/pubmed/15762766 ER -